Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–92. https://doi.org/10.1016/j.jalz.2011.03.003.

Article  PubMed  Google Scholar 

Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The Amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry. 2021;26:5481–503. https://doi.org/10.1038/s41380-021-01249-0.

Article  PubMed  PubMed Central  Google Scholar 

Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s association workgroup. Alzheimers Dement. 2024;20:5143–69. https://doi.org/10.1002/alz.13859.

Article  PubMed  PubMed Central  Google Scholar 

Cummings J. Anti-Amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer’s disease therapeutics. Drugs. 2023;83:569–76. https://doi.org/10.1007/s40265-023-01858-9.

Article  PubMed  PubMed Central  Google Scholar 

Chapleau M, Iaccarino L, Soleimani-Meigooni D, Rabinovici GD. The role of amyloid PET in imaging neurodegenerative disorders: A review. J Nucl Med. 2022;63:S13–9. https://doi.org/10.2967/jnumed.121.263195.

Article  Google Scholar 

Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19. https://doi.org/10.1002/ana.20009.

Article  PubMed  Google Scholar 

Villemagne VL, Mulligan RS, Pejoska S, et al. Comparison of 11 C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2012;39:983–9. https://doi.org/10.1007/s00259-012-2088-x.

Article  PubMed  Google Scholar 

Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H. [18F]Flutemetamol amyloid-beta PET imaging compared with [11 C]PIB across the spectrum of Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2014;41:290–300. https://doi.org/10.1007/s00259-013-2564-y.

Article  PubMed  Google Scholar 

Landau SM, Breault C, Joshi AD, et al. Amyloid-β imaging with Pittsburgh compound B and Florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54:70–7. https://doi.org/10.2967/jnumed.112.109009.

Article  PubMed  Google Scholar 

Pemberton HG, Collij LE, Heeman F, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022;49:3508–28. https://doi.org/10.1007/s00259-022-05784-y.

Article  PubMed  PubMed Central  Google Scholar 

Juréus A, Swahn BM, Sandell J, et al. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem. 2010;114:784–94. https://doi.org/10.1111/j.1471-4159.2010.06812.x.

Article  PubMed  Google Scholar 

Rowe CC, Pejoska S, Mulligan RS, et al. Head-to-head comparison of 11 C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia. J Nucl Med. 2013;54:880–6. https://doi.org/10.2967/jnumed.112.114785.

Article  PubMed  Google Scholar 

Li Y, Zhou K, Zhang X, et al. Fluorine-18-Labeled Diaryl-azines as improved β-Amyloid imaging tracers: from bench to First-in-Human studies. J Med Chem. 2023;66:4603–16. https://doi.org/10.1021/acs.jmedchem.2c01503.

Article  PubMed  Google Scholar 

Wu M, Ren C, Mao C, et al. Evaluation of a novel PET tracer [18F]-Florbetazine for Alzheimer’s disease diagnosis and β-amyloid deposition quantification. NeuroImage. 2024;298:120779. https://doi.org/10.1016/j.neuroimage.2024.120779.

Article  PubMed  Google Scholar 

Ni M, Zhu X, Wang K, et al. Novel β-amyloid PET imaging study of [18F]92 in patients with cognitive decline. ACS Omega. 2024;9(32):34675–83. https://doi.org/10.1021/acsomega.4c03412.

Article  PubMed  PubMed Central  Google Scholar 

Li Y, Zhang X, Zhao H, et al. Screening of [18F]Florbetazine for Aβ plaques and a Head-to-Head comparison study with [11 C]Pittsburgh Compound-B ([11 C]PiB) in human subjects. ACS Pharmacol Transl Sci. 2024;7:2054–62. https://doi.org/10.1021/acsptsci.4c00149.

Article  PubMed  Google Scholar 

Dong L, Liu C, Sha L, et al. PSEN2 mutation spectrum and novel functionally validated mutations in Alzheimer’s disease: data from PUMCH dementia cohort. J Alzheimers Dis. 2022;87:1549–56. https://doi.org/10.3233/JAD-220194.

Article  PubMed  PubMed Central  Google Scholar 

Tan JP, Li N, Gao J, et al. Optimal cutoff scores for dementia and mild cognitive impairment of the Montreal cognitive assessment among elderly and oldest-old Chinese population. J Alzheimers Dis. 2015;43:1403–12. https://doi.org/10.3233/JAD-141278.

Article  PubMed  Google Scholar 

Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913–20. https://doi.org/10.2967/jnumed.109.069088.

Article  PubMed  Google Scholar 

Chapleau M, Iaccarino L, Soleimani-Meigooni D, et al. The role of amyloid PET in imaging neurodegenerative disorders: A review. J Nucl Med. 2022;63:S13–9. https://doi.org/10.2967/jnumed.121.263195.

Article  Google Scholar 

Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959–72.

PubMed  Google Scholar 

Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med. 2011;52:1733–40. https://doi.org/10.2967/jnumed.110.076315.

Article  PubMed  Google Scholar 

Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Sr, et al. The centiloid project: standardizing quantitative amyloid plaque Estimation by PET. Alzheimers Dement. 2015;11:1–15. https://doi.org/10.1016/j.jalz.2014.07.003..e1-4.

Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, et al. Standardization of amyloid quantitation with Florbetapir standardized uptake value ratios to the centiloid scale. Alzheimers Dement. 2018;14:1565–71. https://doi.org/10.1016/j.jalz.2018.06.1353.

Article  PubMed  Google Scholar 

Jagust WJ, Mattay VS, Krainak DM, et al. Quantitative brain amyloid PET. J Nucl Med. 2024;65:670–8. https://doi.org/10.2967/jnumed.123.265766.

Article  PubMed  PubMed Central  Google Scholar 

Villemagne VL, Bourgeat P, Doré V, et al. Amyloid imaging in therapeutic trials: the quest for the optimal reference region [abstract]. Alzheimers Dement. 2015;11:21–2. https://doi.org/10.1016/j.jalz.2015.06.036.

Article  Google Scholar 

Shekari M, Vállez García D, Collij LE, et al. Stress testing the centiloid: precision and variability of PET quantification of amyloid pathology. Alzheimers Dement. 2024;20:5102–13. https://doi.org/10.1002/alz.13883.

Article  PubMed  PubMed Central  Google Scholar 

Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73:1193–9. https://doi.org/10.1212/WNL.0b013e3181bc010c.

Article  PubMed  PubMed Central  Google Scholar 

Landau SM, Lu M, Joshi AD, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Ann Neurol. 2013;74:826–36. https://doi.org/10.1002/ana.23908.

Article  PubMed  PubMed Central  Google Scholar 

Saeed S, Saad JM, Ahmed AI, et al. The utility of positron emission tomography in cardiac amyloidosis. Heart Fail Rev. 2022;27:1531–41. https://doi.org/10.1007/s10741-021-10183-w.

Article  PubMed  Google Scholar 

Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: a practical approach. JACC Cardiovasc Imaging. 2020;13:1368–83. https://doi.org/10.1016/j.jcmg.2019.07.015.

Article  PubMed  Google Scholar 

Ezawa N, Katoh N, Oguchi K, et al. Visualization of multiple organ amyloid involvement in systemic amyloidosis using 11 C-PiB PET imaging. Eur J Nucl Med Mol Imaging. 2018;45:452–61. https://doi.org/10.1007/s00259-017-3814-1.

Article  PubMed